Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CellKine: Allogeneic BM-MSCs for Painful Lumbar Facet Joint Arthropathy
NCT04410731Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2020
- Primary completion
- Mar 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stromal cells in lumbar facet joint arthropathy, sponsored by Mayo Clinic. Primary endpoints: Clinical assessment of nature, incidence, and severity of adverse events (AEs) at 24 months, Self-reported assessment of nature, incidence, and severity of AEs at 24 months and 1 more. Started Apr 2020; status: completed.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
lumbar facet joint arthropathy
Beyond the preview
Go deeper on NCT04410731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04410731.